Vicki L. Goodman - Jan 4, 2022 Form 4 Insider Report for EXELIXIS, INC. (EXEL)

Role
EVP, Prod Dev & Med Aff &CMO
Signature
/s/ Christopher J. Senner, Attorney in Fact
Stock symbol
EXEL
Transactions as of
Jan 4, 2022
Transactions value $
-$146,017
Form type
4
Date filed
1/6/2022, 07:02 PM
Next filing
Feb 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EXEL Common Stock Award $0 +250K $0.00 250K Jan 4, 2022 Direct F1, F2, F3
transaction EXEL Common Stock Tax liability -$146K -7.61K -3.05% $19.18 242K Jan 4, 2022 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.
F2 The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as follows: 26,315 shares subject to the restricted stock unit award vested on the Transaction Date; 59,868 shares subject to the restricted stock unit award will vest on February 15, 2023; 59,869 shares subject to the restricted stock unit award will vest on February 15, 2024; and 51,974 shares subject to the restricted stock unit award will vest on each of February 15, 2025 and February 15, 2026.
F3 Includes 223,685 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
F4 Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded on the Transaction Date.